Introduction and objectives

Table 1. Sample description

<table>
<thead>
<tr>
<th>Disease Condition</th>
<th>Patients</th>
<th>Male</th>
<th>Age</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCV Sample*</td>
<td>729</td>
<td>411</td>
<td>34</td>
</tr>
<tr>
<td>CHD</td>
<td>136</td>
<td>80</td>
<td>60</td>
</tr>
<tr>
<td>CHD and HCV Sample*</td>
<td>252</td>
<td>148</td>
<td>31</td>
</tr>
</tbody>
</table>

Table 2. Direct cost description - CHDs caused by HCV

<table>
<thead>
<tr>
<th>Disease Condition</th>
<th>Direct cost items</th>
<th>Conventional treatment</th>
<th>Unconventional treatment</th>
<th>Hospitalizations</th>
<th>Outpatient medical visits and examinations</th>
<th>Formal caregiving</th>
<th>Traveling/accommodation</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCV</td>
<td>HCV direct costs</td>
<td>€166.76 ± €10.64</td>
<td>€150.16 ± €10.64</td>
<td>€147.26 ± €10.64</td>
<td>€142.26 ± €10.64</td>
<td>€137.26 ± €10.64</td>
<td>€134.26 ± €10.64</td>
</tr>
<tr>
<td>CHD</td>
<td>CHD direct costs</td>
<td>€108.65 ± €10.64</td>
<td>€92.05 ± €10.64</td>
<td>€90.25 ± €10.64</td>
<td>€85.25 ± €10.64</td>
<td>€81.25 ± €10.64</td>
<td>€78.25 ± €10.64</td>
</tr>
<tr>
<td>CHD and HCV Sample*</td>
<td>CHD and HCV Sample*</td>
<td>€149.65 ± €10.64</td>
<td>€133.05 ± €10.64</td>
<td>€131.25 ± €10.64</td>
<td>€126.25 ± €10.64</td>
<td>€122.25 ± €10.64</td>
<td>€119.25 ± €10.64</td>
</tr>
</tbody>
</table>

Table 3. Indirect cost description - CHDs caused by HCV

<table>
<thead>
<tr>
<th>Disease Condition</th>
<th>Indirect costs</th>
<th>Reduced efficiency of non-leisure activities</th>
<th>Lost working days</th>
<th>Reduced efficiency in non-working leisure activities</th>
<th>Wages lost and productivity reduced</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCV</td>
<td>€166.76 ± €10.64</td>
<td>€108.65 ± €10.64</td>
<td>€108.65 ± €10.64</td>
<td>€108.65 ± €10.64</td>
<td>€108.65 ± €10.64</td>
</tr>
<tr>
<td>CHD</td>
<td>€108.65 ± €10.64</td>
<td>€92.05 ± €10.64</td>
<td>€92.05 ± €10.64</td>
<td>€92.05 ± €10.64</td>
<td>€92.05 ± €10.64</td>
</tr>
<tr>
<td>CHD and HCV Sample*</td>
<td>€149.65 ± €10.64</td>
<td>€133.05 ± €10.64</td>
<td>€133.05 ± €10.64</td>
<td>€133.05 ± €10.64</td>
<td>€133.05 ± €10.64</td>
</tr>
</tbody>
</table>

The study was funded by Epic Oliva and CHARTA Foundation.